NewsFeed Voices Science Insight Innovation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Yelak Biru: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
Yelak Biru/LinkedIn
Jun 16, 2025, 16:24

Yelak Biru: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma

Yelak Biru, President and Chief Executive Officer at International Myeloma Foundation, posted on X:

“Congratulations Dr. Kaur on this iMMagine-1 study result and presentation at EHA 2025
‘Anito-cel utilizes a novel, synthetic antigen-binding domain called the D-Domain, which allows for high transduction efficiency, CAR positivity, and CAR density on the T-cell surface. Coupled with a fast off rate and ability to detach from the BCMA target, [this provides] us with a safe and efficacious product,’ lead study author Gurbakhash Kaur said during the presentation.
  • Anito-cel achieved a 97% overall response rate in relapsed/refractory multiple myeloma patients with at least three prior therapies, with a stringent complete response rate of 68%.
  •  The novel D-Domain in anito-cel enhances transduction efficiency and safety, contributing to its efficacy in the iMMagine-1 trial.
  • Safety data showed manageable cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, with most cases resolving quickly.
  • Anito-cel is being further evaluated in the phase 3 iMMagine-3 trial against standard-of-care therapy for relapsed/refractory multiple myeloma.”

Title: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma

Author: Chris Ryan

Read The Full Article at OncLive25.

Yelak Biru: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma

Find More Posts on Hemostasis Today.

Chris Ryan EHA 2025 Gurbakhash Kaur Hematology Hemostasis Today multiple myeloma Yelak Biru
NewsFeed